Pertuzumab และ Trastuzumab ในมะเร็งเต้านม HER2-Positive ระยะเริ่มเป็น

33-Breast metastatic trastuzumab three weekly trastuzumab Possible Side Effects of Trastuzumab · Heart Problems · Infusion-Related Side Effects · Lung Problems · Low White Blood Cell Count (Leukopenia trastuzumab Trastuzumab is a biologic antineoplastic agent that, at the time of its FDA approval in 1998, was among the first available targeted chemotherapies

trastuzumab Trastuzumab deruxtecan is an effective new treatment for patients with HER2-positive metastatic breast cancer who have been previously treated